The market for contract research in China is growing as much as 30 percent a year, compared with less than 10 percent globally, Credit Suisse’s Du said.
The current market size for cough syrups in China is approximately RMB 5 to 10 billion annually and is rapidly growing. We currently estimate that our sales of Laiyang Pear Cough Syrup in China will reach RMB 500 million within the next five years."
Recommendation Summary* Mean Recommendation (this week): 1.0 Mean Recommendation (last week): 1.0 Change: 0.00
* (Strong Buy) 1.0 - 5.0 (Sell) Compare to Industry Price Target Summary Mean Target: 14.00 Median Target: 14.00 High Target: 14.00 Low Target: 14.00 No. of Brokers: 1
"der grüne sternchen... geber darf sich ruhig auch mal äussern :-)"
was soll man hier noch schreiben - alle Infos hast Du gegeben. Dieser Wert ist eines der Perlen die für etwas langfristig orientierte Anleger fast ein "MUSS" darstellt.
Sehr gutes Vertriebsnetz, reichlich Cash, super Produkte und .......
Es ist manchmal etwas frustierend, aber nach 100-200% kommen die ersten zum Gratulieren ;)
lg,
Hummel
----------- 1.Beim Kauf einer Aktie muss man Phantasie haben, beim Verkauf Weisheit 2.Für die Kursentwicklung einer Aktie ist es wichtig was in der Zukunft geschehen wird und nicht was heute geschieht.
After a heavy and seemingly irrational 2 week sell-off, investors regained their senses and drove JGBO up by 22 percent on Monday on strong volume. This swiftly reversed a descending triple bottom alert that came last Friday into a strong Monday reversal, priming the pump for a run back to more reasonable valuation levels. Look for a convincing move above $10.00, then the next significant resistance level at $12.00.
One stock with great potential upside is Jiangbo. Now trading at well below the value of its $100 million in cash holdings, with a forward PE of only about 2x, this is one of the most undervalued companies I have seen. The stock has been battered recently, dropping over 25 percent in the past two weeks despite a complete absence of negative news. The company is a steady money maker with solid prospects, but for reasons that are unclear to me, investors have treated it as though it's going out of business. Many comparable companies are trading for 3 to 5 times as much as Jiangbo; it could double in price and still be undervalued.
Fortunately management has indicated it will address its challenges, with the hiring of a COO as a big next step. I am treating this latest dip as a rare buying opportunity. With uplisting to the NASDAQ on the near-term horizon and with strong projected results for the rest of the year, JGBO look positively cheap at this level.
Die GMP Rezertifikation ist ja positiv verlaufen und deshalb hatte es ja die Produktionspause gegeben..deshalb sollte der nächste Zwischenbericht wieder sehr gut ausfallen....
7€-8€ Einstiegspreise sind absolute Abstauberpreise..imo !!!
The decrease in sales volume was primarily attributable to a loss of production time due to the Good Manufacture Practice ( “GMP”) re-certification procedure and the increased market competition as a result of the newly announced National Basic Medical Insurance in China. The GMP re-certification procedure generally is performed by the Chinese SFDA every five years and it required the production needs to be stopped for the production lines under inspection. The re-certification procedure lasted for approximately six weeks at our main facility in the second quarter of fiscal year 2010. The Company subsequently passed the GMP re-certification and successfully renewed its GMP certificate in December 2009. Our major products are also facing increasing market competition from similar products included in the National Basic Medical Insurance. As our main facility has returned to its normal operation and we have reinforced our sales effort since; we expect our revenue to improve for the remainder of the year.
Thread abonnieren
